The global Cardiac Safety Assessment Services market size is predicted to grow from US$ 798 million in 2025 to US$ 1458 million in 2031; it is expected to grow at a CAGR of 10.6% from 2025 to 2031.

Cardiac safety assessment is an important, animal or animal tissue-based experimental procedure that must be considered before entering into clinical trials. In the past few years, some drugs that have been put into clinical use have had to be withdrawn from the market or their approval has been delayed because of their potential cardiotoxicity or causing severe cardiac arrhythmias.

Drug-induced cardiotoxicity is one of the main reasons for new drugs to be discontinued or removed from the market. Therefore, cardiac safety assessment is a mandatory experimental procedure for various new drugs before entering clinical trials. At present, hERG assay (hERG Assay) (hERG assay is to evaluate the inhibitory effect of drugs on hERc current in stable expression cell lines) is considered to be the existing gold standard for preclinical cardiac safety assessment, and it is also the necessary information for new drug approval required by FDA.

Pharmaceutical companies invest in R&D to deliver high-quality and innovative products to the market, and current trends show that top pharmaceutical companies are increasing R&D efficiency through substantial R&D investments to achieve long-term ROI and through collaborative R&D efforts, which will help increase demand for preclinical and clinical services, including cardiac safety assessments.

LPI (LP Information) newest research report, the ?Cardiac Safety Assessment Services Industry Forecast? looks at past sales and reviews total world Cardiac Safety Assessment Services sales in 2024, providing a comprehensive analysis by region and market sector of projected Cardiac Safety Assessment Services sales for 2025 through 2031. With Cardiac Safety Assessment Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cardiac Safety Assessment Services industry.

This Insight Report provides a comprehensive analysis of the global Cardiac Safety Assessment Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cardiac Safety Assessment Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Cardiac Safety Assessment Services market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cardiac Safety Assessment Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cardiac Safety Assessment Services.

This report presents a comprehensive overview, market shares, and growth opportunities of Cardiac Safety Assessment Services market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Preclinical Cardiac Safety Assessment
    Clinical Cardiac Safety Assessment

Segmentation by Application:

    Commissioned Research Institute
    Pharmaceutical Company
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration.

    Laboratory Corporation of America Holdings
    Metrion
    Clario
    Banook Group
    Iqvia
    Celerion
    Certara
    Biotrial
    Medpace
    Physiostim
    Richmond Pharmacology
    Ncardia
    Pharmaceutical Product Development Llc.
    Reaction Biology
    Eurofins Discovery
    Altasciences
    NEXEL
    charles river
    Scottish Institute of Electrophysiology
    Ronovation Biotech
    Elixir Clinical Research